Jasmin Tiro to Early Detection of Cancer
This is a "connection" page, showing publications Jasmin Tiro has written about Early Detection of Cancer.
Connection Strength
7.818
-
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
Score: 0.549
-
Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS. 2018 08 24; 32(13):1861-1870.
Score: 0.494
-
Effects of program scale-up on time to resolution for patients with abnormal screening mammography results. Cancer Causes Control. 2018 Oct; 29(10):995-1005.
Score: 0.494
-
Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol. 2017 Aug; 51(7):650-655.
Score: 0.459
-
County-level outcomes of a rural breast cancer screening outreach strategy: a decentralized hub-and-spoke model (BSPAN2). Transl Behav Med. 2017 06; 7(2):349-357.
Score: 0.454
-
The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23(7):1147-58.
Score: 0.369
-
Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012 Sep; 5(9):1124-30.
Score: 0.324
-
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012 Jul; 27(7):861-7.
Score: 0.312
-
Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine. 2011 Jun 06; 29(25):4238-43.
Score: 0.296
-
Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. JAMA. 2023 11 28; 330(20):1971-1981.
Score: 0.178
-
Racial and Ethnic Disparities in Cervical Cancer Screening From Three U.S. Healthcare Settings. Am J Prev Med. 2023 10; 65(4):667-677.
Score: 0.171
-
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1517-1520.
Score: 0.162
-
T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates. Front Immunol. 2021; 12:624230.
Score: 0.148
-
Anal Cancer and Anal Cancer Screening Knowledge, Attitudes, and Perceived Risk Among Women Living With HIV. J Low Genit Tract Dis. 2021 Jan 01; 25(1):43-47.
Score: 0.145
-
Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. JAMA Otolaryngol Head Neck Surg. 2020 07 01; 146(7):656-664.
Score: 0.140
-
Cost-effectiveness studies of HPV self-sampling: A systematic review. Prev Med. 2020 03; 132:105953.
Score: 0.136
-
Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits. J Med Screen. 2020 09; 27(3):146-156.
Score: 0.135
-
Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer. 2019 03 15; 144(6):1460-1473.
Score: 0.126
-
Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology. 2019 01; 69(1):121-130.
Score: 0.126
-
Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result. J Womens Health (Larchmt). 2019 03; 28(3):384-392.
Score: 0.126
-
Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1398-1406.
Score: 0.124
-
Social Disadvantage, Healthcare Utilization, and Colorectal Cancer Screening: Leveraging Longitudinal Patient Address and Health Records Data. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1424-1432.
Score: 0.123
-
Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Am J Gastroenterol. 2018 05; 113(5):746-754.
Score: 0.119
-
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. JAMA. 2017 09 05; 318(9):806-815.
Score: 0.116
-
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017 04; 65(4):1196-1205.
Score: 0.110
-
Assessing local capacity to expand rural breast cancer screening and patient navigation: An iterative mixed-method tool. Eval Program Plann. 2017 04; 61:113-124.
Score: 0.109
-
Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. Gastroenterology. 2017 02; 152(3):608-615.e4.
Score: 0.109
-
Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017 03; 65(3):875-884.
Score: 0.108
-
Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. Cancer Epidemiol Biomarkers Prev. 2016 11; 25(11):1449-1455.
Score: 0.107
-
Characterizing safety-net providers' HPV vaccine recommendations to undecided parents: A pilot study. Patient Educ Couns. 2016 09; 99(9):1452-60.
Score: 0.106
-
Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med. 2016 Apr; 31(4):372-9.
Score: 0.105
-
Use of Health Behavior Theory in Funded Grant Proposals: Cancer Screening Interventions as a Case Study. Ann Behav Med. 2015 Dec; 49(6):809-18.
Score: 0.102
-
Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. Cancer. 2016 Feb 01; 122(3):456-63.
Score: 0.102
-
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
Score: 0.098
-
Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):791-8.e1.
Score: 0.093
-
Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013 May; 11(5):472-7.
Score: 0.083
-
Interventions to promote repeat breast cancer screening with mammography: a systematic review and meta-analysis. J Natl Cancer Inst. 2010 Jul 21; 102(14):1023-39.
Score: 0.070
-
Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Netw Open. 2023 03 01; 6(3):e234052.
Score: 0.042
-
Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems. JNCI Cancer Spectr. 2023 01 03; 7(1).
Score: 0.042
-
Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Nov 01; 5(11):e2244343.
Score: 0.041
-
Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 11; 164:107307.
Score: 0.041
-
Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial. Contemp Clin Trials. 2022 11; 122:106960.
Score: 0.041
-
Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 02; 12(3):3705-3717.
Score: 0.041
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.041
-
Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol. 2022 12; 20(12):2818-2825.e1.
Score: 0.039
-
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2022 01; 154:106871.
Score: 0.039
-
De-implementation of cervical cancer screening before age 21. Prev Med. 2021 12; 153:106815.
Score: 0.038
-
Anal cancer screening among women with HIV: provider experiences and system-level challenges. AIDS Care. 2022 02; 34(2):220-226.
Score: 0.037
-
Out of reach? Correlates of cervical cancer underscreening in women with varying levels of healthcare interactions in a United States integrated delivery system. Prev Med. 2021 04; 145:106410.
Score: 0.036
-
Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021 05; 19(5):987-995.e1.
Score: 0.035
-
Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020 08; 52(4):701-709.
Score: 0.035
-
Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw Open. 2019 11 01; 2(11):e1914729.
Score: 0.034
-
Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials. 2018 01; 64:77-87.
Score: 0.029
-
Primary care visit use after positive fecal immunochemical test for colorectal cancer screening. Cancer. 2017 Oct 01; 123(19):3744-3753.
Score: 0.028
-
Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System. Am J Med. 2017 Jan; 130(1):93.e1-93.e7.
Score: 0.027
-
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013 Mar; 108(3):425-32.
Score: 0.021